I  U  P  A  C

News & Notices

Organizations & People

Standing Committees

Divisions

Projects

Reports

Publications
. . CI
. . PAC
. . Macro. Symp.

. . Books
. . Solubility Data

Symposia

AMP

Links of Interest

Search the Site

Home Page

 

Pure Appl. Chem. Vol. 73, No. 9, pp. 1445-1458 (2001)

Pure and Applied Chemistry

Vol. 73, Issue 9

 

New chemical structures of hypolipidemic and antiplatelet activity*

Z. Chilmonczyk1,2,#, D. Siluk3, R. Kaliszan3, B. L/ozowicka2, J. Popl/awski2, and S. Filipek4

1Drug Institute, Chel/mska 30/34, 00-725 Warsaw, Poland; 2Institute of Chemistry, University of Bial/ystok, J. Pil/sudskiego 11/4, 15-443 Bial/ystok, Poland; 3Department of Biopharmaceutics and Pharmacodynamics, Medical University of Gdan´sk, Gen. J. Hallera 107, 80-416 Gdan´sk, Poland; 4Department of Chemistry, University of Warsaw, 1 Pasteura St., 02-093 Warsaw, Poland

Abstract: Elevated lipid level is supposed to be one of the main risk factors of atherosclerosis and subsequent cardiovascular disease (and is connected to mortality). Therefore, lipid lowering is one of the major targets in cardiovascular disease treatment and prevention. Also, blood platelets play a pivotal role in the development of atherosclerosis and fatal thrombus formation in the course of coronary heart disease. Therefore, there is a great necessity to acquire drugs inhibiting platelet aggregation and clot generation. The present paper reviews new chemical structures in development for the treatment and prevention of hyperlipidemia, atherosclerosis, and subsequent cardiovascular disease. The authors' recent results are also reported regarding synthesis of a new group of a-asarone analogs. These compounds were identified as an original class of agents exhibiting hypolipidemic and antiplatelet (mice, rats) activities. Although the mechanism of the compounds' pharmacological activity has not been identified, quantum-mechanical calculations allowed structural requirements to be described that correspond to the activity (a hypothetical pseudoreceptor structure). Since it is known that asarone and its derivatives may exhibit genotoxicity, calculations were carried out to identify derivatives of possibly low genotoxic activity.

*Plenary lecture presented at the Hungarian-German-Italian-Polish Joint Meeting on Medicinal Chemistry, Budapest, Hungary, 2 –6 September 2001. Other presentations are published in this issue, pp. 1387-1509.
# Corresponding author.

Back to Contents for access to full text


 

Page last modified 29 November 2001.
Copyright © 2001 International Union of Pure and Applied Chemistry.
Questions or comments about IUPAC, please contact, the Secretariat.
Questions regarding the website, please contact web manager.